Although this could be interesting as alterations affecting the BRAF oncogene represent the main genetic defects in pilocytic astrocytoma (WHO grade I),[47,48] we showed growth-factor-driven rescue during sorafenib in pilocytic astrocytoma cells, suggesting less potential for single application of this RTK inhibitor. The gene discussed is BRAF; the disease is pilocytic astrocytoma.